Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

The negative role of cyclin G in ATM-dependent p53 activation

Oncogene volume 23, pages 5405–5408 (2004)Cite this article

Abstract

Cyclin G is one of the earliest p53 target genes to be identified, but its function in the p53 pathway has been elusive. Although the precise mechanisms of cyclin G in this novel network have not been explored, recent studies have demonstrated that cyclin G is a key regulator of the p53-Mdm2 network. Here we present evidence that cyclin G-mediated p53 regulation is dependent upon the status of ataxia-telangiectasia mutated (ATM) protein, which activates p53 in response to DNA damage. Abrogation of cyclin G enhances p53 accumulation and phosphorylation of p53 at the Ser-15 residue, resulting in cell cycle arrest. Ectopically expressed cyclin G significantly reduces the steady-state levels of p53 as well as that of phosphorylated p53 at Ser-15 after DNA damage in normal human dermal fibroblasts containing normal ATM. However, cyclin G does not cause similar reductions in p53 levels in ATM-mutated cells. We also show that translocation of cyclin G to the nucleus requires functional ATM. Thus, our findings identify a new role of cyclin G in ATM-dependent p53 regulation and in cell cycle regulation during DNA damage.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Alarcon-Vargas D and Ronai Z . (2002). Carcinogenesis, 23, 541–547.

  • Canman CE, Lim D, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB and Siliciano JD . (1998). Science, 281, 1677–1679.

  • Chen X . (2002). Dev. Cell, 2, 518–519.

  • Giaccia AJ and Kastan MB . (1998). Genes Dev., 12, 2973–2983.

  • Jensen MR, Factor VM, Fantozzi A, Helin K, Huh CG and Thorgeirsson SS . (2003). Hepatology, 37, 862–870.

  • Kimura SH, Ikawa M, Ito A, Okabe M and Nojima H . (2001). Oncogene, 20, 3290–3300.

  • Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir E and Oren M . (2001). Genes Dev., 15, 1067–1077.

  • Ohtsuka T, Ryu H, Minamishima YA, Ryo A and Lee SW . (2003). Oncogene, 22, 1678–1687.

  • Okamoto K and Beach D . (1995). EMBO J., 13, 4816–4822.

  • Okamoto K, Kamibayashi C, Serrano M, Prives C, Mumby MC and Beach D . (1996). Mol. Cell. Biol., 16, 6593–6602.

  • Okamoto K, Li H, Jensen MR, Zhang T, Taya Y, Thorgeirsson SS and Prives C . (2002). Mol. Cell, 9, 761–771.

  • Okamoto K and Prives C . (1999). Oncogene, 18, 4606–4615.

  • Reimer CL, Boras AM, Kurdistanni SK, Garreau JR, Chung M, Aaronson SA and Lee SW . (1999). J. Biol. Chem., 274, 11022–11029.

  • Shimizu A, Nishida J, Ueoka Y, Kato K, Hachiya T, Kuriaki Y and Wake N . (1998). Biochem. Biophys. Res. Commun., 242, 529–533.

  • Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E and Kastan MB . (1997). Genes Dev., 11, 3471–3481.

  • Skotzko M, Wu L, Anderson WF, Gordon EM and Hall FL . (1995). Cancer Res., 55, 5493–5498.

  • Smith ML, Kontny HU, Bortnick R and Fornace Jr. AJ . (1997). Exp. Cell Res., 230, 61–68.

  • Tamura K, Kanaoka Y, Jinno S, Nagata A, Ogiso Y, Shimizu K, Hayakawa TT, Nojima H and Okayama H . (1993). Oncogene, 8, 2113–2118.

  • Zauberman A, Lupo A and Oren M . (1995). Oncogene, 10, 2361–2366.

  • Zhao L, Samuels T, Winckler S, Korgaonkar C, Tompkins V, Horne MC and Quelle D.E . (2003). Mol. Cancer Res., 1, 195–206.

Download references

Acknowledgements

We thank T Ouchi for helpful discussion, the technical help of K-T Kim, and W Wong and M Meyer for proof-reading the manuscript. This work was supported in part by Grants CA85681 and CA78356.

Author information

Authors and Affiliations

  1. Hematology/Oncology Division, Cancer Biology Program, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, 02115, MA, USA

    Takao Ohtsuka, Hyung Gu Kim, Kyung-tae Kim & Sam W Lee

  2. The FIRC Institute of Molecular Oncology, Milan, Italy

    Michael R Jensen

Authors
  1. Takao Ohtsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael R Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyung Gu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kyung-tae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sam W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sam W Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohtsuka, T., Jensen, M., Kim, H. et al. The negative role of cyclin G in ATM-dependent p53 activation. Oncogene 23, 5405–5408 (2004). https://doi.org/10.1038/sj.onc.1207693

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207693

Keywords

This article is cited by

Search

Advanced search

Quick links